Related Experiment Video
Updated: Jul 18, 2026
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas
M Kelly Nicholas1, Rimas V Lukas, Nazia F Jafri
1Department of Neurology, University of Chicago, IL 60637, USA. mnichola@neurology.bsd.uchicago.edu
Abstract:
The epidermal growth factor receptor (EGFR) and its ligands figure prominently in the biology of gliomas, the most common tumors of the central nervous system (CNS). Although their histologic classification seems to be straightforward, these tumors constitute a heterogeneous class of related neoplasms. They are associated with a variety of molecular abnormalities affecting signal transduction, transcription factors, apoptosis, angiogensesis, and the extracellular matrix. Under normal conditions, these same interacting factors drive CNS growth and development. We are now recognizing the diverse molecular genetic heterogeneity that underlies tumors classified histologically into three distinct grades. This recognition is leading to new therapeutic strategies targeted directly at specific molecular subtypes. In this article, we will review the role of EGFR and related molecular pathways in the genesis of the normal CNS and their relationship to glial tumorigenesis. We will discuss barriers to effective treatment as they relate to anatomic specialization of the CNS. We will also consider the ways in which specific EGFR alterations common to glioma reflect outcomes following treatment with targeted therapies, all with an eye towards applying this understanding to improved patient outcomes.
Insights
Epidermal growth factor receptor (EGFR) signaling is crucial in brain tumors like gliomas. Understanding EGFR alterations in these central nervous system (CNS) tumors guides targeted therapies for better patient outcomes.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Genetics
Background:
- Gliomas are the most common central nervous system (CNS) tumors, exhibiting significant molecular heterogeneity despite similar histology.
- Epidermal growth factor receptor (EGFR) and its ligands play a key role in glioma biology and CNS development.
- Tumorigenesis involves molecular abnormalities in signaling, transcription, apoptosis, angiogenesis, and extracellular matrix, mirroring normal CNS development pathways.
Purpose of the Study:
- To review the role of EGFR and associated molecular pathways in normal CNS development and glial tumorigenesis.
- To discuss treatment challenges posed by the CNS's unique anatomy.
- To examine how specific EGFR alterations in gliomas correlate with treatment outcomes for targeted therapies.
Main Methods:
- Literature review focusing on EGFR signaling in gliomas.
- Analysis of molecular genetic heterogeneity in CNS tumors.
- Examination of treatment outcomes related to EGFR alterations.
Main Results:
- EGFR pathway dysregulation is a common feature in gliomas.
- Molecular subtypes of gliomas show distinct genetic profiles.
- Specific EGFR alterations are predictive of response to targeted therapies.
Conclusions:
- Recognizing glioma's molecular heterogeneity is key to developing targeted therapies.
- Understanding EGFR's role can improve treatment strategies for CNS tumors.
- Tailoring therapies based on EGFR alterations holds promise for enhancing patient outcomes.
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...